Home › Funds › Bellevue Group AG › PCVX

Bellevue Group AG position in PCVX

VAXCYTE INC · Health Care

Bellevue Group AG reported holding 1,971,935 shares of PCVX (VAXCYTE INC) in its Q2 2026 13F filing — a position valued at US$114.6M, representing 2.41% of its reported portfolio and ranking #12 among its reported holdings. Bellevue Group AG has disclosed PCVX holdings in 9 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)1.97M sh
Reported value held$114.63M
Portfolio Weight2.41%
First reportedQ3 2023
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Bellevue Group AG's PCVX position evolved

Bellevue Group AG first disclosed a stake in PCVX in Q3 2023 at 30,500 shares (US$1.6M). The position peaked in Q2 2026 at 1,971,935 shares, worth US$114.6M. Across 9 filings, Bellevue Group AG increased the stake 2 time(s), trimmed it 4 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 1,971,935 shares valued at US$114.6M — an increase of 781,238 shares quarter over quarter.. Notable position changes include a 48% trim in Q4 2023 (shares rose 9% over the following quarter), a 66% increase in Q2 2026 (shares fell 2% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 30.50K $1.55M New
Q4 2023 15.80K $992.24K Reduce
Q1 2024 13.24K $904.70K Reduce
Q2 2024 14.21K $1.07M Add
Q3 2024 11.98K $1.37M Reduce
Q4 2024 12.04K $985.43K Hold
Q1 2025 11.29K $426.31K Reduce
Q1 2026 1.19M $69.19M New
Q2 2026 1.97M $114.63M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About PCVX and 13F data

PCVX (VAXCYTE INC) is a Health Care company. 35 other funds we track also report a position in PCVX — the largest reported positions include Jupiter Topco LLC (US$1.04B), Janus Henderson Group (US$960.2M), T. Rowe Price Investment Management, Inc. (US$709.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding PCVX

All PCVX fund holders →

FAQ

How long has Bellevue Group AG held PCVX?

Bellevue Group AG has disclosed PCVX holdings in 9 of the last 12 reported quarters, going back to Q3 2023.

What is Bellevue Group AG's current position in PCVX?

As of Q2 2026, Bellevue Group AG holds 1.97M shares of PCVX (VAXCYTE INC), valued at $114.63M, representing 2.41% of its reported portfolio and ranking #12.

Has Bellevue Group AG been buying or selling PCVX?

In the latest 13F filing (Q2 2026), Bellevue Group AG increased its position in PCVX. The position peaked in Q2 2026 at 1.97M shares.

Which other funds hold PCVX?

Other major institutional holders of PCVX include Jupiter Topco LLC, Janus Henderson Group, T. Rowe Price Investment Management, Inc., among 35 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.